ERBB2 and cancer: A number of markers including, MYCN amplification, HER2/neu over-expression, chromosome 17 gain, Trk expression, and CD44 genetic aberrations have proven useful, and the ability to detect risk factors at the time of diagnosis and tailor therapy accordingly could make the treatment of cancer both more effective and less toxic.